Biorithm
Biorithm is a Singapore- and Cambridge, MA-based medtech company that builds the femom obstetric remote monitoring platform, using electrophysiological sensing to non-invasively capture fetal and maternal biometrics for prenatal and postnatal care delivered to healthcare providers and expectant mothers.
- Company typePrivate
- Founded2015
- HeadquartersSingapore, Singapore
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Biorithm does
Biorithm is a private medical technology company founded in 2015 as a spin-off from Nanyang Technological University in Singapore, with dual headquarters in Singapore and Cambridge, Massachusetts. The company develops the femom platform, a comprehensive obstetric remote monitoring solution comprising a clinical-grade fetal-maternal monitor that non-invasively captures electrophysiological signals from the maternal abdomen to record fetal heart rate, maternal heart rate, and uterine activity and converts them to standard CTG traces; a connected suite of point-of-care devices including blood pressure monitors and glucometers; a patient-facing mobile application (femom App) for symptom capture and engagement; and a physician dashboard for remote patient management, risk evaluation, and automated triaging.
The platform serves obstetricians, gynecologists, midwives, and hospital systems seeking to extend prenatal and postnatal care beyond the clinic, with particular focus on managing hypertensive disorders, diabetes, and gestational diabetes mellitus. Its core differentiator is the single-position, single-measurement capture of multiple bio-metrics using electrophysiological sensing, developed in close collaboration with clinicians and university hospitals. The flagship fetal-maternal monitor is explicitly noted as not FDA-cleared and currently in clinical investigation phase, which constrains US commercialization.
Biorithm monetizes through a combination of hardware sales (the fetal-maternal monitor and connected POC devices) and recurring subscription access to the physician dashboard and patient application, sold via a quote-based enterprise sales motion targeting healthcare providers and hospital systems in Southeast Asia and the United States. The company has raised $3.5 million in a December 2023 Series A co-led by Adaptive Capital Partners and SEEDS Capital, with participation from Australian Medical Angels, to fund geographic expansion, clinical research, and global partnerships. The company operates with 11–50 employees and no public revenue or ARR is disclosed.
Biorithm firmographics
Firmographics- Name
- Biorithm
- Legal name
- Biorithm
- Website
- https://bio-rithm.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Biorithm is a Singapore- and Cambridge, MA-based medtech company that builds the femom obstetric remote monitoring platform, using electrophysiological sensing to non-invasively capture fetal and maternal biometrics for prenatal and postnatal care delivered to healthcare providers and expectant mothers.
- Ownership category
- akta.pro rank
Biorithm industry classification
Industry- Product category
- Obstetric Remote Monitoring
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Maternal & Neonatal Remote Monitoring Platforms (HLACAFAC)
- akta.pro secondary industries
- Maternal, Fetal & Neonatal Monitoring (CTG, Infant Wearables) (HLAHACAF), Maternal, Neonatal & Pediatric Remote Monitoring (HLACAPAG), Maternal & High-Risk Pregnancy Remote Monitoring (BP, glucose, fetal/uterine monitoring) (HLALAFAG), Pregnancy & Prenatal Care Telehealth (OB tele-visits, prenatal monitoring) (HLALAHAC)
Keywords
Where Biorithm is headquartered
LocationHeadquarters
- HQ city
- Singapore
- HQ country
- Singapore
- HQ region
- Asia
Offices2 records
Markets served
Biorithm business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Revenue model
- Remote Monitoring Platform Subscription: Subscription-based access to the femom obstetric remote monitoring platform including the physician dashboard and patient app for ongoing maternal health monitoring services.
- Fetal-Maternal Monitor Hardware: Sale of clinical-grade fetal-maternal monitoring devices to healthcare providers and hospitals.
- Connected POC Devices: Point-of-care devices including blood pressure monitors and glucometers sold as part of the integrated maternal monitoring solution.
Go-to-market motion2 records
Distribution channels2 records
Marketing channels2 records
Biorithm product offering
Product offeringCore offering
Biorithm develops and sells the femom obstetric remote monitoring platform, which combines a clinical-grade fetal-maternal monitor (based on electrophysiological signal processing), a patient mobile application, connected point-of-care devices, and a physician dashboard. The platform enables healthcare providers to deliver continuous maternal-fetal care between in-office visits, supporting remote monitoring of high-risk pregnancies including hypertensive disorders, diabetes, and gestational diabetes mellitus.
Product overview
Biorithm offers a unified platform called femom — a comprehensive obstetric remote monitoring solution composed of three integrated components: the femom Fetal-Maternal Monitor (clinical-grade hardware for non-invasive recording of fetal heart rate, maternal heart rate, and uterine contractions), the femom Maternal Monitoring / Femom Lite module (connected care using point-of-care devices and a patient mobile app), and the femom Clinician Dashboard (for remote patient management and clinical decision support). The platform converts electrophysiological signals into CTG traces, enables virtual visits with automated patient triaging, and supports management of complex maternal conditions.
Differentiator
Problem solved
Functional benefit
Brands
- femom: Comprehensive obstetric remote monitoring solution including clinical-grade fetal-maternal monitor, patient mobile application, connected point-of-care devices such as BP monitors and glucometers, and physician dashboard for remote patient management.
- Femom Lite
- Femom Fetal Monitoring
Products and services
- femom Obstetric Remote Monitoring Platform A comprehensive obstetric remote monitoring platform that enables healthcare providers to manage pregnant patients virtually between in-office appointments through a connected ecosystem including clinical-grade fetal-maternal monitor, patient mobile app, connected point-of-care devices, and a physician dashboard for clinical decision support.
- femom Fetal-Maternal Monitor A clinical-grade fetal-maternal monitor (not FDA-cleared, currently in clinical investigation phase) that non-invasively records fetal heart rate, maternal heart rate, and uterine contractions from electrophysiological signals captured on the maternal abdomen, with automatic conversion to CTG trace for clinician review.
- femom Maternal Monitoring (Femom Lite) A connected maternity care solution that enables remote monitoring of maternal vital signs and symptoms through point-of-care devices (blood pressure monitors, glucometers) integrated with a patient mobile application, supporting management of hypertensive disorders, diabetes, and gestational diabetes mellitus.
Quantifiable outcome
- Improved maternal and fetal health outcomes through remote monitoring and early complication detection
Companies that use Biorithm
Customer profileSegments2 records
Ideal customer profiles1 record
Biorithm technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
Biorithm partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core and major.
- Nanyang Technological University (NTU Singapore)coreBiorithm was spun off from NTU Singapore, developed in collaboration with university researchers and hospitals. The company maintains academic partnerships for clinical validation and research.
- University HospitalsmajorClinical partnerships with university hospitals for product development, validation, and clinical studies. Products designed and developed in close collaboration with clinicians and hospital partners.
Scale indicators2 records
Recent moves7 records
Expansion highlights5 records
Biorithm competitors and assessment
Company assessmentDirect peers
- Nuvo Group (Invu): Nuvo Group's Invu platform is a remote pregnancy monitoring system with a wearable belt that captures maternal and fetal heart rate data for clinician review. It is one of the closest direct competitors to Biorithm's femom, targeting the same high-risk pregnancy RPM use case and same obstetric clinician customer base.
- Bloomlife: Bloomlife develops remote maternal health monitoring devices, including a contraction and fetal heart rate sensor worn at home. Like Biorithm, Bloomlife focuses on enabling data-driven, between-visit pregnancy care for clinicians and expectant mothers using connected hardware and a clinician-facing dashboard.
- Babyscripts: Babyscripts is a virtual maternity care platform combining a patient mobile app, connected devices (BP cuffs, weight scales, glucose monitors), and a clinician dashboard for remote monitoring of prenatal and postpartum patients. It directly competes with Biorithm's connected ecosystem approach to obstetric RPM.
- Mahmee: Mahmee is a maternal-infant health platform offering virtual care, in-person support, and RPM tools for pregnancy and postpartum patients. It is comparable to Biorithm in serving the same maternal health use case with a tech-enabled care model and clinician dashboard, though with a stronger services overlay.
- Monica Healthcare: Monica Healthcare (now part of GE HealthCare) pioneered wireless fetal ECG monitoring using abdominal electrophysiology — the same underlying technical principle as Biorithm's femom. It is highly comparable on technology architecture and served as the reference point for the Novii patch product.
Broad incumbents
- Philips (Maternal & Child Health / Avalon): Philips' Avalon series is the market-leading line of fetal and maternal monitors used in hospital labor and delivery units worldwide. As a broad incumbent, Philips competes with Biorithm's femom hardware in clinical monitoring while offering a much wider portfolio of hospital and connected care solutions.
- GE HealthCare (Novii / Monica Healthcare): GE HealthCare's Novii Wireless Patch System (acquired from Monica Healthcare) is a remote fetal/maternal monitoring patch designed for high-risk pregnancies. It directly overlaps with femom's electrophysiological-based fetal monitoring and is sold as part of GE's broad perinatal portfolio.
- Mindray: Mindray is a large medical device manufacturer offering patient monitors and fetal monitoring solutions used in hospitals globally. While broader than Biorithm in scope, Mindray competes in the same hospital fetal-maternal monitoring category and represents a price-sensitive alternative in many markets.
Emerging players
- Owlet Baby Care: Owlet sells connected wearables primarily for infant monitoring but has expanded into pregnancy health (e.g., Owlet Band). It is comparable as a consumer-facing connected maternal/infant health device company, though Owlet's center of gravity remains postpartum and infant care rather than clinical-grade prenatal monitoring.
- HeraBEAT: HeraBEAT is an Israeli medtech company with a handheld, clinical-grade fetal Doppler designed for use by expectant mothers at home. It overlaps with femom's positioning of clinical-grade fetal monitoring delivered into the home, though its single-metric (fetal heart rate) scope is narrower than femom's multi-bio-metric capture.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Biorithm social profiles
Digital presenceBiorithm financial estimates
Financial estimateRevenue estimate
Valuation estimate
Biorithm leadership team
Management profileNumber of profiles
Profiles2 records
Biorithm funding detail
Funding detailFunding overview
Funding rounds2 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Biorithm M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Biorithm
What does Biorithm do?
Biorithm develops and sells the femom obstetric remote monitoring platform, which combines a clinical-grade fetal-maternal monitor (based on electrophysiological signal processing), a patient mobile application, connected point-of-care devices, and a physician dashboard. The platform enables healthcare providers to deliver continuous maternal-fetal care between in-office visits, supporting remote monitoring of high-risk pregnancies including hypertensive disorders, diabetes, and gestational diabetes mellitus.
Is Biorithm a public or private company?
Biorithm is a private company. It is classified as venture growth investor backed and is currently operating.
When was Biorithm founded?
Biorithm was founded in 2015. It employs 11 to 50 people.
Where is Biorithm based?
Biorithm is headquartered in Singapore, Singapore, in the Asia region.
How does Biorithm make money?
Three revenue lines are on record. Remote Monitoring Platform Subscription is the primary driver. The others are fetal-Maternal Monitor Hardware and connected POC Devices.
Who are Biorithm's main competitors?
Direct peers on record are Nuvo Group (Invu), Bloomlife, Babyscripts, Mahmee and Monica Healthcare. Broad incumbents are Philips (Maternal & Child Health / Avalon), GE HealthCare (Novii / Monica Healthcare) and Mindray. Emerging players are Owlet Baby Care and HeraBEAT.
Does Biorithm have an API?
No public API is recorded for Biorithm.
What industry is Biorithm in?
Biorithm's product category is Obstetric Remote Monitoring. Its primary akta.pro industry code is HLACAFAC, Maternal & Neonatal Remote Monitoring Platforms, with a secondary code of HLAHACAF, Maternal, Fetal & Neonatal Monitoring (CTG, Infant Wearables). Its NAICS code is 334510 and its SIC code is 3845.